Connect with us
DAPA Banner

Business

Xiao-I Corp Stock Explodes 157% as China Court Victory Over Apple Patent Bolsters AI Patent Portfolio

Published

on

Xiao-I Corp

Shares of Xiao-I Corp (NASDAQ: AIXI) skyrocketed more than 156% Monday, surging to around $0.34 in afternoon trading as retail investors piled into the micro-cap artificial intelligence company following a major legal victory in its long-running patent dispute with Apple in China.

Xiao-I Corp
Xiao-I Corp

The dramatic intraday move saw the stock open sharply higher and maintain strong momentum, with trading volume spiking to extraordinary levels for the small company. The rally built on earlier gains triggered by news that China’s Supreme People’s Court rejected Apple’s appeal to invalidate key AI patents held by Xiao-I’s variable interest entity (VIE) in Shanghai.

Xiao-I Corporation, a Shanghai-based provider of cognitive intelligence solutions founded in 2001, specializes in natural language processing, conversational AI, knowledge graphs, hyperautomation and multimodal technologies. The company serves sectors including finance, contact centers, government services, manufacturing and healthcare through platforms that integrate deep learning and affective computing.

The patent ruling, finalized on March 27, 2026, affirmed the validity of Xiao-I’s core AI intellectual property that forms the basis of its infringement lawsuit against Apple. The Supreme Court’s decision, which is final and non-appealable on the validity issue, removed a significant legal hurdle and validated the company’s technological claims. While the infringement proceedings continue and no financial compensation is guaranteed, the outcome strengthened Xiao-I’s position in China’s competitive AI landscape.

The stock had already shown volatility in early April. It surged more than 33% on April 2 following initial reports of the court decision, with massive volume reflecting retail enthusiasm. Monday’s continuation pushed the price well above recent levels, though it remained far below its 52-week high near $4 and reflected the stock’s history of sharp swings as a low-float micro-cap name.

Advertisement

Analysts and market observers described the move as driven primarily by sentiment and short-term momentum rather than fundamental shifts in operations. Xiao-I’s market capitalization stayed under $5 million even after the surge, underscoring its status as a highly speculative play. The company has faced challenges including dilution from convertible notes, governance issues and limited revenue scale compared with global AI leaders.

Despite the legal win, risks remain substantial. The broader infringement case against Apple entities in China is ongoing, and outcomes on damages or licensing are uncertain. Xiao-I operates primarily through a VIE structure, a common but complex arrangement for foreign-listed Chinese companies that carries inherent regulatory and ownership risks.

The company’s core offerings include a conversational AI platform, knowledge fusion tools, intelligent voice systems and hyperautomation solutions. It has positioned itself as a pioneer in cognitive intelligence since its early days, with applications in smart city services, financial institutions and industrial digitization. Revenue comes from software licenses, maintenance services and cloud-based AI products.

Recent company updates highlighted client renewals in the automotive sector and continued development of metaverse and vision analysis platforms. However, like many small AI firms, Xiao-I competes against much larger players with deeper resources, including domestic giants and international technology firms.

Advertisement

Monday’s trading frenzy echoed patterns seen in other low-priced, news-driven stocks where retail participation on platforms can amplify moves. Volume exceeded typical daily averages by multiples, with significant pre-market and intraday interest. Some traders noted the stock breaking technical levels, including attempts to reclaim the 50-day moving average for the first time in months.

Wall Street coverage of AIXI is limited due to its size. Price targets and ratings are sparse, and the stock carries high volatility warnings. Investors are cautioned about the potential for rapid reversals, as micro-cap names often experience profit-taking after sharp rallies.

For long-term holders, the patent victory could enhance licensing opportunities or strengthen negotiating power in China’s AI ecosystem. Yet execution risks, competition and the need for sustained revenue growth remain key concerns. The company has emphasized its 20-plus years of R&D in cognitive technologies and partnerships across industries.

As of Monday afternoon, AIXI traded with elevated volatility, reflecting the speculative nature of the move. Broader market sentiment, including interest in Chinese AI plays amid geopolitical and regulatory developments, may have contributed to the enthusiasm.

Advertisement

Xiao-I Corporation went public on Nasdaq in 2023 through an American Depositary Shares offering. Its business model focuses on industrializing AI technologies for practical enterprise applications rather than consumer-facing products. The firm maintains research centers and collaborates with universities and industry partners.

Retail investors on forums and social platforms celebrated the surge, with some calling it validation of the company’s IP strength. Skeptics warned of classic pump dynamics in low-float stocks and urged caution, noting the absence of immediate revenue impact from the court ruling.

Company officials have stated they will continue updating shareholders on material developments in the Apple litigation. No specific timeline for resolution of the remaining infringement claims has been provided.

In the wider AI sector, patent battles are increasingly common as companies seek to protect innovations in natural language processing, machine learning and related fields. Xiao-I’s win, while significant for the firm, highlights the strategic importance of intellectual property in China’s rapidly evolving technology market.

Advertisement

Monday’s price action pushed the stock well into positive territory for the session, though it continued to trade as a high-risk name with limited institutional following. Market participants will watch for any follow-through momentum or profit-taking in coming sessions.

Xiao-I Corp, with roughly 162 employees, operates from Shanghai and focuses on delivering AI solutions that drive industrial digitization and intelligent transformation. Its technologies power applications from intelligent customer service to smart city initiatives.

As trading continued Monday, the surge in AIXI served as a reminder of the speculative opportunities — and risks — in small-cap AI stocks reacting to legal or technological developments. Investors are advised to conduct thorough due diligence, considering the company’s financial position, competitive landscape and the uncertain path from patent validation to commercial success.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Sticker Mule demands Google fix ‘mislabeled’ ads tied to political campaign

Published

on

Sticker Mule demands Google fix 'mislabeled' ads tied to political campaign

Sticker Mule is demanding Google fix what it says is a “misleading” error that labeled its business ads as funded by its CEO’s political campaign.

In a legal letter obtained by FOX Business, the company said its ads were incorrectly tagged in Google’s Ads Transparency Center as “Paid for by Constantino for Congress,” despite having no ties to campaign financing. Sticker Mule CEO Anthony Constantino, a Republican, is running for Congress in New York’s 21st District.

Advertisement

“This mislabeling is erroneous, misleading, and must be immediately and permanently corrected,” the company wrote. ” … Sticker Mule has never used Constantino for Congress funds to pay for its ads, nor have any Sticker Mule ads promoted Anthony Constantino as a political candidate.”

The company said the issue likely stems from a technical glitch in Google’s election ad verification system — possibly triggered by an employee logged into both business and campaign ad accounts during verification.

GOOGLE CO-FOUNDER RIPS CALIFORNIA BILLIONAIRE TAX: ‘I FLED SOCIALISM’

Screenshots from Google’s Ads Transparency Center show Sticker Mule ads labeled as

Screenshots from Google’s Ads Transparency Center appear to show Sticker Mule ads labeled as “Paid for by Constantino for Congress.” (@constantino via X)

Sticker Mule noted Google had previously acknowledged and temporarily fixed the problem after it was flagged.

Advertisement

The company is now calling on Google to remove the label, explain the root cause, confirm the fix in writing and ensure it does not happen again. 

If not resolved, Sticker Mule said it may escalate the issue to federal regulators, including the Federal Trade Commission (FTC) and the Federal Election Commission (FEC).

The dispute comes as Constantino faces a March 2026 FEC complaint alleging he improperly used campaign funds to promote his business. The complainant is described in filings as an ally of Assemblyman Robert Smullen, his Republican primary opponent.

Constantino denied the allegations, calling them “meritless” and blaming Google’s labeling error. He also noted some of the ads cited date back to 2023, before his campaign existed.

Advertisement

SOCIAL MEDIA TRIAL VERDICT: WHAT HAPPENS NOW, HOW MUCH WILL TECH GIANTS REALLY PAY?

Sticker Mule CEO Anthony Constantino speaks at an event in New York.

Sticker Mule CEO Anthony Constantino speaks at an event in New York.  (Paul Antonelli)

“For some reason they were mislabeled and we asked Google to fix that as it’s hurting our brand. Smullen has already been served with multiple cease and desists for lying,” Constantino wrote in a March 30 post on X.

Smullen has pushed back, disputing the explanation, according to WPTZ.

“It’s quite clear that my opponent has been violating the federal law, having to do with co-mingling his business and campaign activities and funds,” Smullen said. “He’s been lying about it, this whole thing.”

Advertisement

Earlier this year, President Donald Trump endorsed Constantino in the race.

“It is my Great Honor to endorse America First Patriot, Anthony Constantino, who is running to represent the fantastic people of New York’s 21st Congressional District,” Trump wrote on Truth Social.

TECH CEO WHO WENT VIRAL FOR PRO-TRUMP EMAIL DEFENDS CALL TO ACTION OVER ‘POLITICAL HATE’

Google Office In San Diego

A Google logo is displayed outside an office building on December 12, 2025, in San Diego, California. (Kevin Carter/Getty Images / Getty Images)

Constantino told Fox News Digital at the time that he spoke with Trump and was honored to receive the nod. 

Advertisement

“He noted every primary candidate he endorses wins, so I look forward to winning the general election and making everyone who supported me very proud once I am in Congress,” Constantino said.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Google and Smullen did not immediately respond to FOX Business’ request for comment.

Fox News Digital’s Brian Flood and Louis Casiano contributed to this report.

Advertisement
Continue Reading

Business

Persimmon flags cost inflation and softening demand

Published

on

Business Live

Persimmon says new home enquiries have ‘softened slightly’ but the FTSE 100 housebuilder is still seeing higher forward sales

The housebuilder completed 14,551 homes in 2021, with an average selling price of £237,078

Persimmon is issued a warning over escalating supply costs

Yorkshire housebuilder Persimmon has raised concerns over escalating supply costs linked to the Iran conflict, as demand starts to ease. The firm, one of Britain’s biggest housebuilders, announced it is beginning to encounter inflationary pressures within its supply chain, which it warned could affect its finances as early as the second half of this year.

Advertisement

The Government is relying on housebuilders to deliver its target of 1.5m homes, yet industry figures have cautioned that building material costs could surge as a result of the Iran conflict.

The FTSE 100 company said: “There are early signs of increased inflation in the supply chain, driven by higher energy costs, which are likely to impact the second half of 2026 and into 2027. We are looking to mitigate these where possible through our strong relationships with our suppliers and subcontractors.”, as reported by City AM.

However, the housebuilder confirmed it has yet to witness any “material impact” from the ongoing Middle East conflict. Despite the looming threat of inflation, Persimmon reported that net sales per week are 3% up on last year, with forward-looking sales up by 7% to £1.8bn.

The housebuilder’s share price climbed by more than 2% in early trading, reaching 1,053p, as stockbrokers praised the company’s robustness.

Advertisement

Mark Crouch, analyst at eToro, said: “Persimmon’s update suggests a housing market that, for now, is holding firm, but the bigger picture for UK housebuilders is rapidly darkening. Persimmon’s numbers look solid enough, forward sales up, pricing holding firm, and volumes broadly in line with expectations.”

Property analysts have cautioned that expectations of interest rates remaining elevated for longer owing to the Iran conflict have prompted Britons to delay home purchases, as they await more favourable mortgage rate offers. Persimmon reported that enquiries for new properties have “soften slightly” in recent weeks, though the housebuilder noted that sales have remained “resilient”.

“We continue to be mindful of the potential effects on consumer confidence and affordability, with some increases in mortgage rates seen since early March,” the company stated.

In its full-year update at the close of last year, the housebuilder highlighted a “supportive” economic climate, as the construction and property sectors bounced back from a spell of uncertainty surrounding the Budget. Persimmon recorded an 11% rise in profit, climbing to £397m in the year ending December.

Advertisement

However, sentiment around housebuilders has shifted markedly since the Iran conflict started in February, as demand for house purchases has taken a knock from concerns that interest rates will remain higher for an extended period. Earlier this week, Taylor Wimpey became the latest housebuilder to temper its outlook with a cautious update, warning that construction costs could be poised to increase.

And earler this month, Barratt Redrow – Britain’s biggest housebuilder – announced it would significantly reduce its land acquisition spending, pointing to the need for prudence given the economic fallout from the Iran war. Meanwhile, housebuilder Berkeley saw its share price tumble at the beginning of the month after announcing it would halt land purchases entirely, citing an “unprecedented increase in cost and regulation”.

Like this story? For more news from the property scene around the regions, visit our dedicated section here for the latest news and analysis within the sector.

Advertisement
Continue Reading

Business

USDA Tries to Ease Fertilizer Price Pain for Farmers

Published

on

Patrick Thomas hedcut

The Trump administration is trying to tame surging fertilizer prices—and thinks suppliers might be part of the problem.

U.S. Agriculture Secretary Brooke Rollins said Tuesday that the administration was taking several actions, such as temporarily loosening shipping restrictions, increasing imports and launching a Justice Department investigation into the major U.S. fertilizer companies.

​Rollins said the USDA was also reviving a Biden administration-era program that pledged $900 million in funding to build new fertilizer plants in the U.S. About 30% of the world’s nitrogen fertilizer supply travels through the Strait of Hormuz, which has been blocked because of the war in Iran. ​About 75% of the nitrogen fertilizer market in the U.S. is controlled by four companies, Rollins said.

Continue Reading

Business

Eli Lilly (LLY) earnings Q1 2026

Published

on

Eli Lilly (LLY) earnings Q1 2026

David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026.

Aaron Schwartz | Bloomberg | Getty Images

Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the healthcare sector. 

Advertisement

Here’s what Wall Street is expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $6.66 adjusted expected
  • Revenue: $17.62 billion expected

Demand for the company’s blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro has helped fuel several solid quarters for Lilly, which holds the majority market share in the booming GLP-1 space. 

Analysts expect Zepbound to rake in overall sales of $4.04 billion, with $3.98 billion coming from the U.S., according to StreetAccount estimates. Meanwhile, they expect Mounjaro to book worldwide sales of $7.26 billion, including U.S. revenue of $3.87 billion, StreetAccount estimates said. 

The company’s newly approved GLP-1 pill for obesity, Foundayo, launched in the second quarter, so its sales won’t be included in Thursday’s report.

Still, the pill’s rollout is likely to dominate the discussion during Lilly’s first-quarter earnings call. Executives will likely face questions about whether Foundayo can reach the same level of momentum as the rival Wegovy pill from Novo Nordisk, which benefited from a three-month head start in the U.S.

Advertisement

It’s too soon to assess the performance of Lilly’s pill. But early prescription data suggest its initial rollout has been “modest,” according to a note last week from Leerink Partners analyst David Risinger. 

In February, Lilly said it expects to benefit from Foundayo’s launch, Medicare coverage of obesity drugs coming online later this year and continued worldwide demand for Mounjaro and Zepbound. But the company also expects to face pricing pressure, driven by a drug pricing deal with President Donald Trump and lower cash-pay prices for Zepbound, among other factors. 

Still, Lilly CEO Dave Ricks said in an interview in late April that he expects lower prices to accelerate prescription volumes in the U.S. He also estimated that global GLP-1 use will rise from approximately 20 million patients at the end of last year to 30 million at the end of 2026.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Business

Murphy USA Inc. (MUSA) Q1 2026 Earnings Call Prepared Remarks Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Christian Pikul
Vice President of Investor Relations & FP&A

Good afternoon, everyone, and thanks for listening in today. With me are Mindy West, President and Chief Executive Officer; and Donnie Smith, Chief Financial Officer. After some opening comments from Mindy, Donnie will review some performance highlights from the first quarter, followed by some closing comments from Mindy.

As a reminder, we will be publishing a transcript and recorded playback of these remarks this afternoon, and then we will host a live Q&A session tomorrow morning at 10:00 a.m. Central Time. Details can be found on our Investor Relations website and in today’s earnings release.

Please keep in mind that some of the comments made during these remarks, including the Q&A portion tomorrow, will be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. As such, no assurances can be given that these events will occur or that the projections will be attained. A variety of factors exist that may cause actual results to differ. For further discussion of risk factors, please see the latest Murphy USA Forms 10-K, 10-Q, 8-K and other recent SEC filings. Murphy USA takes no duty to publicly update or revise any forward-looking statements.

Advertisement

During today’s discussion, we may also provide certain performance measures that do not conform to Generally Accepted Accounting Principles or GAAP. We have provided schedules to reconcile these non-GAAP measures with the reported results on a GAAP basis as part of our earnings press release, which can be found on the Investors section of our website.

Continue Reading

Business

Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What’s driving the surge?

Published

on

Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?
The shares of CRDMO player Syngene rallied nearly 17% on Thursday, even after the company reported a 19% year-on-year drop but a strong sequential surge in net profit to Rs 148 crore for the fourth quarter of the financial year 2026, along with key management changes.

While the company’s net profit dropped over 19% from the Rs 183 crore reported in the fourth quarter of the previous financial year, it saw a multi-fold increase from the Rs 15 crore net profit reported in the third quarter of FY26. The net profit for the reported quarter included a gratuity re-measurement credit of Rs 20 crore arising from revised labour codes, and Rs 25 crore exceptional loss related to termination benefits extended to employees in accordance with the approved policy.

Revenue from operations, meanwhile, grew nearly 2% to Rs 1,036.5 crore in Q4 FY26, from Rs 1,018 crore in the corresponding quarter of the previous financial year. Sequentially, revenue grew more than 13% QoQ from Rs 917.1 crore reported in Q3 FY26.

Syngene said that its profit after tax before exceptional items fell 16% YoY to Rs153 crore in the January-March quarter of the financial year which ended on March 31, 2026.

Advertisement

Key leadership changes

Indian industrialist Kiran Mazumdar-Shaw who transitioned from the role of Non Executive Chairman to Executive Chairman from April 1 onwards, said she is pleased to have taken the role at a pivotal moment in the company’s growth journey. “I look forward to working with the new leadership team to shape our next phase of expansion, as we continue to benefit from the rising global demand for outsourcing across the life sciences sector. While biotech funding remains discerning and largely concentrated on late-stage assets, Syngene’s diversified end-to-end business model—from discovery and development to manufacturing gives us both resilience and strategic agility in navigating these market realities. We are also focused on building new business lines, strengthening our differentiated service offerings, and investing in AI and digital capabilities that will enhance speed, productivity, and value creation for our clients,” she said.

Syngene International’s Managing Director and CEO Peter Bains meanwhile said that Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with its revised full-year guidance. “The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth,” he said.
Notably, Syngene announced that Siddharth Mittal has been appointed Managing Director and CEO of the company, effective from July 1, 2026, for a five-year term. He will succeed Peter Bains. Mittal earlier served as the Managing Director and CEO of Biocon.
“Q4 reported growth at 2% and 13% sequentially reflects the ongoing product impact in our largest biologics customer, resulting in full year growth of 3%. Operating EBITDA margin at 25% for the year reflects this impact and additional operating costs as we bring the new biologics manufacturing facility in India into operations. We generated Rs. 521 Cr of cash during the year, post capex investment, strengthening our balance sheet,” said the company CFO Deepak Jain.
Notably, Maninder Kapoor Puri will take over as the company’s Chief Human Resources Officer from May 1 onwards. She previously led the human resources function at Biocon.

Macquarie on Syngene

Macquarie maintained its ‘Outperform’ rating on Syngene shares, with a target price of Rs 835 apiece, CNBC-TV18 reported. This implies an upside potential of more than 93% from the stock’s previous closing price of Rs 432.15 apiece.

The international brokerage was quoted as saying by the business news channel that EBITDA was 11% ahead of its estimates, while the adjusted net profit of Rs 150 crore was 8% below expectations.

Syngene share price

Syngene shares rallied nearly 17% to trade at Rs 505.60 apiece in the afternoon. The stock has gained over 17% in one week and nearly 29% in one month. The shares of the company are however down nearly 23% in 2026 so far.

Advertisement

In the longer term, the shares of the company dropped 21% in one year, 26% in three years and over 9% in five years. The company currently has a market capitalisation of nearly Rs 20,280 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Continue Reading

Business

Volkswagen AG 2026 Q1 – Results – Earnings Call Presentation (NEOE:VWA:CA) 2026-04-30

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Bank Polska Kasa Opieki 2026 Q1 – Results – Earnings Call Presentation (OTCMKTS:BKPKF) 2026-04-30

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Now up 169%+: A new list of AI-picked stocks for April IS NOW LIVE

Published

on

Now up 169%+: A new list of AI-picked stocks for April IS NOW LIVE


Now up 169%+: A new list of AI-picked stocks for April IS NOW LIVE

Continue Reading

Business

Antero Resources: Another Storm Fern Beneficiary

Published

on

Antero Resources: Another Storm Fern Beneficiary

Antero Resources: Another Storm Fern Beneficiary

Continue Reading

Trending

Copyright © 2025